10 Tips to Consider when Planning for Accountability, Reconciliation and Destruction of Clinical Trial Material

All experimental compounds tested in humans during clinical development are under stringent control to ensure that these drugs are administered only to eligible patients participating in approved study protocols. To that end, regulatory agencies worldwide mandate that all investigational products manufactured for clinical trials must have cradle-to-grave tracking for accountability, reconciliation, and destruction. You can reduce this burden and streamline the process by considering and implementing these 10 easy tips, that will ultimately save money, minimize errors, and more efficiently reconcile all IP at study closeout per regulatory requirements.